Burden of transfusion‐transmitted infections among patients with thalassaemia and sickle cell anaemia in India: A systematic review and meta‐analysis
Transfusion Medicine · 2026-04 · 36 (2) · 121-132
DOI: 10.1111/tme.70044 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Transfusion Medicine, online erschienen am 28.11.2025. Verfasst von Vaibhav Shandilya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Employees State Insurance Corporation (ESIC) Medical College and Hospital, Hyderabad, India. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Thalassemia, Transfusion Reaction, Blood Transfusion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Lifelong blood transfusions, crucial for severe cases of thalassaemia and sickle cell disease (SCD), contribute to a high risk of transfusion‐transmitted infections (TTIs). The current systematic review and meta‐analysis determined the prevalence of transfusion‐transmitted infections (TTIs) among patients with thalassaemia and sickle cell anaemia in India. A systematic search was conducted in PubMed, Scopus, ProQuest, EMBASE and Web of Science for articles published up to September 13, 2025. Title abstract screening followed by full‐text review and data extraction was done by two independent reviewers. Risk of bias was assessed for the included studies. Meta‐analysis was conducted to estimate the pooled prevalence of TTIs. The systematic review and meta‐analysis identified 397 unique articles, with 39 selected for full‐text review. After exclusions, 24 studies spanning from 1990 to 2023 were included. All 24 studies included patients with beta thalassaemia, whereas only one study had data on sickle cell anaemia patients, so this review focuses mainly on the prevalence of TTI in patients with beta thalassaemia. The pooled prevalence of Hepatitis C was 22% (95% CI: 14%–30%; I 2 = 96%), Hepatitis B was 8% (95% CI: 2%–16%; I 2 = 96%) and HIV was 4% (95% CI: 2%–7%; I 2 = 77%) in beta‐thalassaemia patients, all showing high heterogeneity. Meta‐regression revealed a statistically significant decline over time in HBV (Beta = −0.0194, p =
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Employees State Insurance Corporation (ESIC) Medical College and Hospital, Hyderabad, India.
- Department of Community Medicine, All India Institute of Medical Sciences, Nagpur, India.
- Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Transfusion Medicine, All India Institute of Medical Sciences (AIIMS), Nagpur, India.
- Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
ORCID-Profile: Savitha Seetharaman, Divjot Singh Lamba, Soumya Das, Bijaya Kumar Padhi, Aravind P Gandhi
Zitieren
APA
Shandilya, V., Seetharaman, S., Parmeswaraiah Geetha, S., Lamba, D. S., Das, S., Padhi, B. K., & Gandhi, A. P. (2026). Burden of transfusion‐transmitted infections among patients with thalassaemia and sickle cell anaemia in India: A systematic review and meta‐analysis. Transfusion Medicine, 36(2), 121-132. https://doi.org/10.1111/tme.70044
Vancouver
Shandilya V, Seetharaman S, Parmeswaraiah Geetha S, Lamba DS, Das S, Padhi BK, et al. Burden of transfusion‐transmitted infections among patients with thalassaemia and sickle cell anaemia in India: A systematic review and meta‐analysis. Transfusion Medicine. 2026;36(2):121-132. doi:10.1111/tme.70044
BibTeX
@article{Shandilya2026,
author = {Shandilya, Vaibhav and Seetharaman, Savitha and Parmeswaraiah Geetha, Sahana and Lamba, Divjot Singh and Das, Soumya and Padhi, Bijaya Kumar and Gandhi, Aravind P},
title = {Burden of transfusion‐transmitted infections among patients with thalassaemia and sickle cell anaemia in India: A systematic review and meta‐analysis},
journal = {Transfusion Medicine},
year = {2026},
volume = {36},
number = {2},
pages = {121--132},
doi = {10.1111/tme.70044}
}
EUVIMED